Sporadic hypercalcitoninemia: Clinical and therapeutic consequences

Endocrine-Related Cancer

Volumn 16, Issue 1, 2009, Pages 243-253

  Scheuba, Christian ^a   Kaserer, K ^a   Moritz, A ^b   Drosten, R ^c   Vierhapper, H ^a   Bieglmayer, C ^a   Haas, O A ^b   Niederle, Bruno ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; PENTAGASTRIN; PROTEIN RET; DIAGNOSTIC AGENT; RET PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; CALCITONIN BLOOD LEVEL; CANCER STAGING; CELL HYPERPLASIA; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GERM LINE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NECK DISSECTION; PREDICTION; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TUMOR VOLUME; ADOLESCENT; BLOOD; FOLLOW UP; GENETICS; MEDULLARY CARCINOMA; MIDDLE AGED; MUTATION; PROSPECTIVE STUDY; THYROID TUMOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CALCITONIN; CARCINOMA, MEDULLARY; FEMALE; FOLLOW-UP STUDIES; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; PENTAGASTRIN; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 65549129116     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-08-0059     Document Type: Article

References (48)

1. Albores-Saavedra JA & Krueger JE 2001 C-cell hyperplasia and medullary thyroid microcarcinoma. Endocrine Pathology 12 365-377.
2. Barbot N, Calmettes C, Schuffenecker I, Saint-Andre JP, Franc B, Rohmer V, Jallet P & Bigorgne JC 1994 Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 78 114-120.
3. Bieglmayer C, Scheuba C, Niederle B, Flores J & Vierhapper H 2002 Screening for medullary thyroid carcinoma: experience with different immunoassays for human calcitonin. Wiener Klinische Wochenschrift 114 267-273.
4. Boi F, Maurelli I, Pinna G, Atzeni F, Piga M, Lai ML & Mariotti S 2007 Calcitonin measurement in wash-out fluid from fine needle aspiration of neck masses in patients with primary and metastatic medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 92 2115-2118.
5. Bugalho MJ, Santos JR & Sobrinho L 2005 Preoperative diagnosis of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement. Journal of Surgical Oncology 91 56-60.
6. Castro MR & Gharib H 2005 Continuing controversies in the management of thyroid nodules. Annals of Internal Medicine 142 926-931.
7. Cheung K, Roman SA, Wang TS, Walker HD & Sosa JA 2008 Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost effectiveness and decision analysis. Journal of Clinical Endocrinology and Metabolism 93 2173-2180.
8. Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, Crocetti U, Attard M, Maranghi M, Torlontano M et al. 2007 Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. Journal of Clinical Endocrinology and Metabolism 92 450-455.
9. Deftos LJ 2004 Should serum calcitonin be routinely measured in patients with thyroid nodules - will the law answer before endocrinologists do? Journal of Clinical Endocrinology and Metabolism 89 4768-4769 (author reply 4769-4770).
10. Deftos LJ, Bone HG III & Parthemore JG 1980 Immunohistological studies of medullary thyroid carcinoma and C cell hyperplasia. Journal of Clinical Endocrinology and Metabolism 51 857-862.
11. Demers L & Spencer C 2003 Laboratory support for diagnosis and monitoring of thyroid disease. National Academy of Clinical Biochemistry, Washington DC, www.nacb.org/lmpg/thyroid.
12. Dralle H 2002 Lymph node dissection and medullary thyroid carcinoma. British Journal of Surgery 89 1073-1075.
13. Dunn JT 1994 When is a thyroid nodule a sporadic medullary carcinoma? Journal of Clinical Endocrinology and Metabolism 78 824-825.
14. Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L, Miccoli P, Iacconi P, Basolo F, Pinchera A et al. 2004 Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10 864 patients with nodular thyroid disorders. Journal of Clinical Endocrinology and Metabolism 89 163-168.
15. Eng C 1996 Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. New England Journal of Medicine 335 943-951.
16. Fink M, Weinhäusel A, Niederle B & Haas OA 1996 Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. 'Study Group Multiple Endocrine Neoplasia Austria (SMENA)'. International Journal of Cancer 69 312-316.
17. Hahm JR, Lee MS, Min YK, Lee MK, Kim KW, Nam SJ, Yang JH & Chung JH 2001 Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid 11 73-80.
18. Hegedus L 2004 Clinical practice. The thyroid nodule. New England Journal of Medicine 351 1764-1771.
19. Hodak SP & Burman KD 2004 The calcitonin conundrum-is it time for routine measurement of serum calcitonin in patients with thyroid nodules? Journal of Clinical Endocrinology and Metabolism 89 511-514.
20. Horvit PK & Gagel RF 1997 The goitrous patient with an elevated serum calcitonin - what to do? Journal of Clinical Endocrinology and Metabolism 82 335-337.
21. Iacobone M, Niccoli-Sire P, Sebag F, De Micco C & Henry JF 2002 Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operated patients with elevated serum calcitonin levels World Journal of Surgery 26 8.
22. Karanikas G, Moameni A, Poetzi C, Zettinig G, Kaserer K, Bieglmayer C, Niederle B, Dudczak R & Pirich C 2004 Frequency and relevance of elevated calcitonin levels in patients with neoplastic and nonneoplastic thyroid disease and in healthy subjects. Journal of Clinical Endocrinology and Metabolism 89 515-519.
23. Kaserer K, Scheuba C, Neuhold N, Weinhäusel A, Vierhapper H, Haas OA & Niederle B 1998 C-cell hyperplasia and medullary thyroid carcinoma in patients routinely screened for serum calcitonin. American Journal of Surgical Pathology 22 722-728.
24. Kaserer K, Scheuba C, Neuhold N, Weinhäusel A, Vierhapper H & Niederle B 2002 Recommendations for reporting C cell pathology of the thyroid. Wiener Klinische Wochenschrift 114 274-278.
25. Kebebew E, Ituarte PH, Siperstein AE, Duh QY & Clark OH 2000 Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88 1139-1148.
26. Kebebew E, Greenspan FS, Clark OH, Woeber KA & Grunwell J 2005 Extent of disease and practice patterns for medullary thyroid cancer. Journal of the American College of Surgeons 200 890-896.
27. Lips CJ, Hoppener JW & Thijssen JH 2001 Medullary thyroid carcinoma: role of genetic testing and calcitonin measurement. Annals of Clinical Biochemistry 38 168-179.
28. LiVolsi VA 1997 C cell hyperplasia/neoplasia (editorial; comment). Journal of Clinical Endocrinology and Metabolism 82 39-41.
29. Matias-Guiu X, Peiro G, Esquius J, Oliva E, Cabezas R, Colomer A & Prat J 1995 Proliferative activity in C-cell hyperplasia and medullary thyroid carcinoma. Evaluation by PCNA immunohistochemistry and AgNORs staining. Pathology, Research and Practice 191 42-47.
30. McDermott MB, Swanson PE & Wick MR 1995 Immunostains for collagen type IV discriminate between C-cell hyperplasia and microscopic medullary carcinoma in multiple endocrine neoplasia, type 2a. Human Pathology 26 1308-1312.
31. Niccoli P, Wion-Barbot N, Caron P, Henry JF, de Micco C, Saint Andre JP, Bigorgne JC, Modigliani E & Conte-Devolx B 1997 Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. Journal of Clinical Endocrinology and Metabolism 82 338-341.
32. Ozgen AG, Hamulu F, Bayraktar F, Yilmaz C, Tuzun M, Yetkin E, Tuncyurek M & Kabalak T 1999 Evaluation of routine basal serum calcitonin measurement for early diagnosis of medullary thyroid carcinoma in seven hundred seventy-three patients with nodular goiter. Thyroid 9 579-582.
33. Pacini F, Fontanelli M, Fugazzola L, Elisei R, Romei C, Di Coscio G, Miccoli P & Pinchera A 1994 Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma (see comments). Journal of Clinical Endocrinology and Metabolism 78 826-829.
34. Papi G, Corsello SM, Cioni K, Pizzini AM, Corrado S, Carapezzi C, Fadda G, Baldini A, Carani C, Pontecorvi A et al. 2006 Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: a multicenter study. Journal of Endocrinological Investigation 29 427-437.
35. Perry A, Molberg K & Albores-Saavedra J 1996 Physiologic versus neoplastic C-cell hyperplasia of the thyroid: separation of distinct histologic and biologic entities. Cancer 77 750-756.
36. Rieu M, Lame MC, Richard A, Lissak B, Sambort B, Vuong-Ngoc P, Berrod JL & Fombeur JP 1995 Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules (see comments). Clinical Endocrinology 42 453-460.
37. Rosai J, Carcangiu ML & DeLellis RA 1992 Atlas of Tumor Pathology: Tumors of the Thyroid Gland. Washington, DC: Armed Forces Institute of Pathology.
38. Scheuba C, Kaserer K, Weinhäusel A, Pandev R, Kaider A, Passler C, Prager G, Vierhapper H, Haas OA & Niederle B 1999 Is medullary thyroid cancer predictable? A prospective study of 86 patients with abnormal pentagastrin tests (in process citation) Surgery 126 1089-1095 (discussion 1096).
39. Scheuba C, Kaserer K, Kotzmann H, Bieglmayer C, Niederle B & Vierhapper H 2000 Prevalence of C-cell hyperplasia in patients with normal basal and pentagastrin-stimulated calcitonin. Thyroid 10 413-416.
40. Scheuba C, Bieglmayer C, Asari R, Kaczirek K, Izay B, Kaserer K & Niederle B 2007 The value of intraoperative pentagastrin testing in medullary thyroid cancer. Surgery 141 166-171 (discussion 171-162).
41. Scollo C, Baudin E, Travagli JP, Caillou B, Bellon N, Leboulleux S & Schlumberger M 2003 Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 88 2070-2075.
42. Sheppard MC 1995 Should serum calcitonin be measured routinely in all patients with nodular thyroid disease? Clinical Endocrinology 42 451-452.
43. Shine B 2002 Routine calcitonin measurement in management of thyroid nodules: a decision analysis approach. In Endorine Abstracts. Ed ECoE 2007: BioScientifica Ltd.
44. Verga U, Ferrero S, Vicentini L, Brambilla T, Cirello V, Muzza M, Beck-Peccoz P & Fugazzola L 2007 Histopathological and molecular studies in patients with goiter and hypercalcitoninemia: reactive or neoplastic C-cell hyperplasia? Endocrine-Related Cancer 14 393-403.
45. Vierhapper H, Raber W, Bieglmayer C, Kaserer K, Weinhäusl A & Niederle B 1997 Routine measurement of plasma calcitonin in nodular thyroid diseases. Journal of Clinical Endocrinology and Metabolism 82 1589-1593.
46. Vierhapper H, Niederle B, Bieglmayer C, Kaserer K & Baumgartner-Parzer S 2005 Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders. Thyroid 15 1267-1272.
47. Wittekind C, Compton CC, Greene FL & Sobin LH 2002 TNM residual tumor classification revisited. Cancer 94 2511-2516.
48. Wittekind C, Greene FL, Hutter RVP, Sobin LH, Henson DC (eds) 2003 TNM Supplement: a commentary on uniform use (3rd ed) Hoboken, UK: Wiley.